GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer

GH Research PLC (GHRS) — Dr. Popova will lead the clinical development of GH001 as the company advances toward pivotal programs in TRD and PPDBrings more than 20 years of global pharmaceutical R&D experience at Johnson & Johnson across clinical operations, clinical development, regulatory strategy, and neuroscience portfolio leadershipClinical lead in the Spravato® (esketamine) program, where she led TRANSFORM-2, one of the pivotal Phase 3 trials that supported its approval in TRD, and was lead author of the trial publi

Source: GlobeNewswire — read the full announcement there.

See our GH Research company profile for background, links, and more GH Research news.